AIM ImmunoTech Inc. (AIM)
Automate Your Wheel Strategy on AIM
With Tiblio's Option Bot, you can configure your own wheel strategy including AIM - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol AIM
- Rev/Share 0.0021
- Book/Share -0.0548
- PB -173.2263
- Debt/Equity -0.1483
- CurrentRatio 0.2646
- ROIC -0.6432
- MktCap 7260271.0
- FreeCF/Share -0.2196
- PFCF -0.4701
- PE -43.933
- Debt/Assets 0.0915
- DivYield 0
- ROE -15.8623
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
AIM ImmunoTech Announces NYSE American Notice of Noncompliance With Minimum Stockholders' Equity Requirements
Published: June 20, 2025 by: GlobeNewsWire
Sentiment: Neutral
NYSE American previously issued similar warning for same matter and issued the new notice because the deficiency remains as of March 31, 2025
Read More
AIM ImmunoTech Announces Trading Under the Ticker AIMI on the Pink Open Market
Published: April 07, 2025 by: GlobeNewsWire
Sentiment: Neutral
OCALA, Fla., April 07, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (“AIM” or the “Company”) (OTC Pink: AIMI) — an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19 — announced that as of today its common stock is trading under the ticker AIMI on the Pink Open Market and the Special Meeting on April 30, 2025, about a reverse split is still on.
Read More
AIM ImmunoTech Inc. (AIM) Q4 2024 Earnings Call Transcript
Published: April 01, 2025 by: Seeking Alpha
Sentiment: Neutral
AIM ImmunoTech Inc. (NYSE:AIM ) Q4 2024 Earnings Conference Call April 1, 2025 8:30 AM ET Company Participants Thomas Equels - Chief Executive Officer, President and Executive Vice Chairman Conference Call Participants Ed Woo - Ascendiant Capital Markets Operator Hello and welcome to the AIM ImmunoTech Fourth Quarter and Full Year 2024 Update Conference Call and Webcast. As a brief reminder, all participants are currently in a listen-only mode.
Read More
Aimia Inc. (AIMFF) Q4 2024 Earnings Call Transcript
Published: March 28, 2025 by: Seeking Alpha
Sentiment: Neutral
Aimia Inc. (OTCPK:AIMFF) Q4 2024 Results Conference Call March 28, 2025 8:30 AM ET Company Participants Joe Racanelli - Vice President of Investor Relations Tom Finke - Executive Chairman Rhys Summerton - Incoming Executive Chairman Steven Leonard - President and Chief Financial Officer Conference Call Participants Brian Morrison - TD Cowen Operator Good morning, ladies and gentlemen, and welcome to Aimia Inc. Fourth Quarter 2024 Results Conference Call. At this time, all lines are in listen-only mode.
Read More
AIM announces Paul Goepfert, MD, as the principal investigator for the planned clinical study of Ampligen and FluMist as a vaccine for avian influenza
Published: February 28, 2025 by: GlobeNewsWire
Sentiment: Neutral
Proposed study of Ampligen as a vaccine adjuvant to increase cross-reactivity to influenza strains Proposed study of Ampligen as a vaccine adjuvant to increase cross-reactivity to influenza strains
Read More
AIM ImmunoTech Releases Virtual Investor “What This Means Segment”
Published: February 11, 2025 by: GlobeNewsWire
Sentiment: Neutral
Tom Equels, CEO of AIM ImmunoTech and Professor Casper H.J. van Eijck, MD, PhD, Pancreato-biliary Surgeon at Erasmus MC, discuss the Phase 1b/2 clinical trial involving AIM's Ampligen® (rintatolimod) and AstraZeneca's anti-PD-L1 immune checkpoint inhibitor Imfinzi® (durvalumab) in the treatment of late-stage pancreatic cancer (“DURIPANC”) Watch the “What This Means” segment here
Read More
About AIM ImmunoTech Inc. (AIM)
- IPO Date 1996-07-12
- Website https://www.aimimmuno.com
- Industry Biotechnology
- CEO Mr. Thomas K. Equels Esq., J.D., M.S.
- Employees 21